Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Antigen Presentation Suppliers Serving Europe
37 companies found
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inAbingdon, UNITED KINGDOM
Thermally Stable Needle Free Solid Dose Vaccines. Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies. These diseases affect millions of ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process ...
based inMainz, GERMANY
Fuelled by Innovation: With a pioneering spirit and high technical expertise, ORGENTEC has become firmly established in medical diagnostics. Our employees’ talent and skills establish the basis for our success. At our headquarters in Mainz, Germany, ...
Anti-DGP IgA is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgA antibodies against deamidated gliadin protein epitopes (DGP) in human serum or plasma. These assays are used to support a diagnosis of celiac ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Senti Bio has established, and continues to scale, a powerful Design-Build-Test-Learn development engine to generate our therapeutic gene circuits. Unique to Senti Bio’s approach is the speed, quantity and quality of the multiple types of gene ...
based inLangenfeld, GERMANY
ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production. We develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ...
based inSeocho-gu, NORTH KOREA
We, JW Holdings, are moving forward toward global healthcare group. JW Holdings, as a holding company, we are concentrating all our efforts to ensure stable growth of business companies including JW Pharmaceutical, JW Shinyak, JW Life Science, JW ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within ...
based inOxford, UNITED KINGDOM
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease ...
Recombinant Chikungunya Virus-Like Particles produced in mammalian HEK293 cells. Chikungunya structural proteins are transiently expressed to form a particle comprising E1, E2 and capsid protein, without the non-structural proteins or genome. ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, ...
based inWayne, PENNSYLVANIA (USA)
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and ...
Purity:> 97 % as determined by SDS-PAGE. Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method. ...
based inNiel, BELGIUM
eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platform includes mRNA construct design and optimization, proprietary ...
Our mRNA platforms and vast in-house experience help partners quickly optimize, screen and select an mRNA code, develop a candidate, and ensure effective & prime manufacturing of the mRNA from research grade to GMP scale. Our platform’s ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
CRM197 has been tested in animals studies and it has been demonstrated to lack toxicity. CRM197 can be used as a carrier protein for vaccine delivery. It acts by helping polysaccharide antigens to bind on and be internalized into ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inNew Orleans, LOUISIANA (USA)
Our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious ...
based inMunich, GERMANY
ImevaX is a Biotech company based in Munich with a focus on facilitating H. pylori Diagnostics with a novel Rapid Diagnostic ...
(cytotoxin-associated antigen A) is one of the best studied and most important virulence factors. Subjects infected with H. pylori strains expressing CagA have a significant higher risk to develop complications, including gastric cancer, compared to ...